IPO
The good performance we saw in the second quarter has continued and further improved.
The new license agreement with Zimmer Biomet contributed to that we delivered the strongest quarter to date for Bactiguard as a listed company.
Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB.” Total gross proceeds from the issuance of new shares amounted to USD 582 million (DKK 3,873 million) with a corresponding increase in share capital of 3,277,500 ordinary shares or 32,775,000 ADSs
Esperion provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019.
China-US trade challenges has led to de-risking by pharma companies
The Annual General Meeting of BioArctic AB on May 9, 2019, adopted instructions regarding the appointment of the Nomination Committee.
Sygnature Discovery has added in-house high-throughput screening (HTS) to its range of drug discovery services.
Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, will announce a trading update for the nine-months ended 30 September 2019 on Tuesday, 5 November 2019.
Recipharm, the contract development and manufacturing organisation, and CTC Clinical Trial Consultants have strengthened their partnership with the divestment of Recipharm’s GLP bioanalysis business to the Center for Translational Research AB group.
Amgen announced that it has agreed to acquire a 20.5% stake in BeiGene for approximately $2.7 billion in cash and concurrently has entered into a strategic collaboration pursuant to which BeiGene will commercialize XGEVA®, KYPROLIS® and BLINCYTO® in China and advance 20 medicines from Amgen’s innovative oncology pipeline in China and globally.
PRESS RELEASES